Datasheet is currently unavailable. Try again or CONTACT US
TRAF6 Antibody
Rabbit Polyclonal IgG
200-401-I32
100 µg
Liquid
WB, FC
Human
Rabbit
Shipping info:
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Product Details
Anti-TRAF6 (RABBIT) Antibody - 200-401-I32
RNF85, NF receptor-associated factor 6, E3 ubiquitin-protein ligase TRAF6, Interleukin-1 signal transducer, RING finger protein 85
Rabbit
Polyclonal
IgG
Target Details
TRAF6 - View All TRAF6 Products
Human
Conjugated Peptide
TRAF6 Antibody was produced from whole rabbit serum prepared by repeated immunizations with a peptide corresponding to an internal amino acid sequence in the human protein TRAF6.
Anti-TRAF6 Antibody was purified by Protein G chromatography. A BLAST analysis was used to suggest cross-reactivity with Anti-TRAF6 from human and mouse based on 100% homology with the immunizing sequence. Cross-reactivity with Anti-TRAF6 from other sources has not been determined.
Application Details
FC, WB
Anti-TRAF6 Antibody is tested for use in WB and FLOW. Expect a band approximately 54kDa on specific lysates. Specific conditions for reactivity should be optimized by the end user.
Formulation
0.5 mg/mL by UV absorbance at 280 nm
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
0.05% (w/v) Sodium Azide
0.05% BSA
Shipping & Handling
Dry Ice
Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration date is one (1) year from date of receipt.
Anti-TRAF6 Antibody detects human TRAF6. Tumor necrosis factor (TNF) induced signaling is mediated through association of TNF receptor (TNFR) with adaptor proteins, such as TNF receptor associated proteins (TRAFs). TRAFs form a family of cytoplasmic adapter proteins that mediate signal transduction from many members of the TNF-receptor superfamily (e.g. RANK, CD30, CD40, etc.) and the interleukin-1 receptor. The carboxy-terminal region of TRAFs is required for self-association and interaction with receptor cytoplasmic domains following ligand-induced oligomerization. Recent molecular cloning studies have lead to identification of six TRAFs (TRAF1-TRAF6). Recently it has been shown that TRANCE/OPGL activates the antiapoptotic serine/threonine kinase Akt/PKB through a signaling complex involving c-Src and TRAF6. Mice deficient in TNF receptor-associated factor 6 (TRAF6) are osteopetrotic with defects in bone remodeling and tooth eruption due to impaired osteoclast function. Like TRAF2 and TRAF3, TRAF6 is also essential for perinatal and postnatal survival. These findings establish unexpectedly diverse and critical roles for TRAF6 in perinatal and postnatal survival, bone metabolism, LPS, and cytokine signaling. RANK (TRANCE receptor) interacts with various TRAFs through distinct motifs and activates NF-kB via a novel TRAF6 interaction motif, which then activates NIK, thus leading to NF-kB activation. Over-expression of TRAF6 activates JNK, p38, or IKK in the absence of extracellular stimulation. Anti-TRAF6 Antibody is ideal for investigators involved in Toll Like Receptors and signaling, cytokines, growth factors and AKT Signaling.
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.